Elevated plasma concentrations of von Willebrand factor (vWf) are increasingly recognized as a cardiovascular risk factor, and are used as a marker of endothelial activation. However, the factors which deter mine the rate of vWf release from the endothelium in vivo have not been defined clearly. In addition, vWf plasma levels may also be influ enced by adhesion of vWf to the vascular waIl or to platelets, and by its rate of degradation. The propeptide of vWf (also called vWf:Agll) is stored and released in equimolar amounts with vWf. In the present study we attempted to determine whether this propeptide could be a more reliable marker of endothelial secretion than vWf itself. To acc omplish this we developed an ELISA based on monoclonal antibodies. The propeptide levels in normal plasma were found to be 0.7 p.g/ml, more than 10 times lower than vWf itself. Administration of desmo pressin (DDAVP) induced a rapid relative increase in propeptide (from 106 to 879%) and in vWf (from 112 to 272%). However, the increases in vWf and propeptide were equivalent when expressed in molar units. A time course study indicated a half-life of the propeptide of 3 h or less. In a baboon model of disseminated intravascular coagulation (DIC) in duced by FXa, vWf increased by less than 100%, whereas the propep tide concentrations increased by up to 450%. In view of the massive thrombin generation (as assessed by fibrinogen depletion), the increas es in vWf are small, compared to the strong secretory response to thrombin and fibrin previously observed in vitro. Our results suggest that due to its rapid turnover, the propeptide could provide a sensitive plasma marker of acute endothelial secretion.
Introduction
Plasma von Willebrand factor (vWf) is increasingly recognized as a predictor of cardiovascular mortality. As shown by the ECAT study and other reports, elevations in plasma vWf, along with tissue plasmi nogen activator (t-PA) and fibrinogen (1,2), predict myocardial infarc tion in patients with angina pectoris. Plasma vWf is elevated in severe hypertension (3) , diabetic nephropathy (4, 5) and end-stage renal failure (6) . It is a predictor of the excess cardiovascular disease associated with these conditions, and is often considered as a marker of endothe liai activation. vWf is synthesized, stored and secreted by megakaryo cytes/platelets and by endotheliai cells (7) . Since the plasma pooi main ly originates from endothelial ceNs (8) , it can be assumed that plasma vWf leveis are determined by the rate of endothelial release (8) .
In endothelial celis vWf is stored in speciaiized secretory granules, called Weibei-Paiade bodies (7) , and released after stimulation by thrombin or other mediators of thrombosis and/or inflammation (e.g. histamine, complement C5a and C5b-9) (9.12). Thrombin may act directly on its receptor on endothelial ceils, or indirectly by generating fibrin, which in turn induces endothelial secretion (10) . In addition, hormones such as epinephrine and vasopressin can induce an increase in plasma vWf. lndeed, the vasopressin analog DDAVP is used clini cally to increase plasma vWf and to shorten bieeding time (13.15) . We have recently observed that epinephrine can induce vWf release from Weibei-Palade bodies in vitro after activation of~3-adrenergic recep tors, although it isa much less potent stimulus than thrombin (Vischer and Wollheim, submitted). The relative contribution of these factors to the determination of plasma vWf concentration is presently unknown.
The assessment of endothelial vWf secretion has severai potential limitations, fluctuations in plasma vWf are usually small, and tend to overiap with normal values, which display a fairly wide range (16) . vWf is released from endothelial ceils on the baso-lateral side (17) . A part of the secreted vWf may therefore remain trapped in the sub-endo thelium at the site of release (18), and fail to reach the bloodstream. The fraction retained could be modified in vascular disorders. Further, vWf levels may be affected by changes in its clearance. If it is released in a thrombogenic context, vWf may be rapidly consumed in the process of platelet aggregation (19) . Accelerated proteolytic degradation of vWf, which circulates as complex multimers, has been suggested in patients with severe arterial disease (20) . Plasma vWf concentrations are influ enced by blood groups, presumably because the protein cardes ABO antigens which influence its clearance rate (21, 22) . Finally, the long haif-life of vWf in the circulation (approx. 12 h) (23) implies that even extensive release by the endothelium may resuit in only modest relative increases in plasma vWf.
vWf is synthesized as a large 360 kf) precursor, pro-vWf. After undergoing dimerization and glycosylation in the endoplasmic reticu lum and the Golgi apparatus, the precursor reaches the trans-Golgi net work where it undergoes multimerization of the dimers and cleavage into mature vWf and an unusually large, 97 kf) propeptide. Both frag ments are directed to the Weibel-Palade bodies, as they remain asso ciated by non-covalent, pH-dependent interactions. Stimulation of exo cytosis therefore causes the release of equimolar amounts of vWf and (7, 24, 25) . The propeptide has a simpler molecular structure than vWf itself (e.g. it does not undergo multimerization) and seems flot to adhere to platelets or to vascular structures [although it contains an integrin binding RGD sequence (7)]. The plasma propeptide levels could therefore be an attractive candidate marker of endothelial secre tion in vivo. McCarrroH et al. (26) used the difference between mature vWf and propeptide levels to identify patients with type II von Wille brand disease, attributing the lower levels of vWf to an accelerated clearance.
The present study was undertaken 10 investigate whether the plasma propeptide could be a better marker cf endothelial exocytosis than vWf itself. We constructed a quantitative ELISA procedure to measure plas ma propeptide levels and tested it in two model situations of acute vWf release, i.e. the response 10 the injection of DDAVP in normal individu aIs and an experimental disseminated intravascular coagulation (DIC) in the baboon.
Methods
Propepude ELISA
We set up a sandwich-type ELISA based on monoclonal antibodies. Monoclonais BR5 and 8H10 have been previously characterized (27) and were kind ly prcvided by Dr. P. Fay (Rochester NY). Monoclonal 3H4 was generated by injecting balb/c mice with WP body fractions (28) . The puiified antibody stains Weibel-Palade bodies by indirect immunofluorescence in cultured human um bilical vein endothelial ceils (HUVEC5) and recognizes unreduced purified propeptide by Western Blot (not shown).
96-well plates were coated with antibodies BR5 and 3H4 0.75 ig)ml each in carbonate buffer (NaCO3 50 mM, pH 9.6), 100 iIiwell. After 4 washes with TBS-T (Tris 20 mM, NaCI 140 mM, Tween-20 0.1%, pH 7.4), the remaining protein binding sites were blocked with 150 p.Wwell blocking solution (TBS-T + 5% dry skim milk). Samples and standards diluted in blocking solution were added and incubated for 2 h at 370 C. After 4 washes with TBS-T, antibody 8H10 conjugated to alkaline phosphalase diluted 1:800 (approx. 0,25 tiglml) was added for 90 min al 37°C. Sound alkaline phosphalase activity was detect ed using p-nitrophenyl phosphate as a substrate rad measuring optical density at405 nm.
Purified plasma propeptide was generously provided by Dr. P. J. Fay (29) . The protein content was determined by die Bradford assay, using bovine serum aibumin as a standard. This preparation contained a single 97 kfla hand on su ver staining of an overloaded gel (2 p.gllane). The purified protein was used as a standard, allowing us to determine die propeptide concentration in normal pooled plasma (NPP). For routine assays, a standard curve was constructed with NPP. Each sample was tested at 4 dilutions. Resuits are expressed either as a percentage of NPP, or converted te p.g/ml (assuming a concentration of 0.72 p.gIml in NPP, sec results). Resuits for baboon propeptide are aiways expressed as a percentage of a reference baboon plasma.
A range cf normal values was determined on citrated plasma from 30 healthy individuals (age range 20-60 years).
vWf was measured by ELISA as previcusly described (30) . Mean vWf levels in 22 baboon samples was 121 ± 19% (mean ± SD) compared to human pooled plasma, and the (10g (OD) y. log (concj) relations of human and baboon samples were parallel. Unless staled otherwise, results are expressed as means ± SEM. Statisticai comparison between groups was done using the paired, two-tailed Student's t-test.
DDAVP Studies
Nine normal healthy volunteers (4 men and 5 women, median age 24, range 21-44) received a single intravenous infusion of desmopressin (Minirin, Ferring AG), given at a dose of 0.4 p.g/kg body weight intravenously over 30 mm, as previousiy described (31) . The volunteers gave informed consent and the pro tocol was approved by die local ethics committee. Biood was drawn before and I h after the end cf the infusion. vWf and propeptide were measured on citrat cd plasma. Five additional volunteers were injected with desmopressin subcu taneously, and blood was collected before md I, 3, rad 6 h after the injection.
Disseminaied Iniravascuior Coagulation (DIC) Studies
Baboons (papio ursinus) weighing 25-30 kg were quarantined for three months on arrivai and screened for evidence of disease before being reIeased from quarantine. They were housed individually in a facility accredited by the French ministry of Agriculture, and fed with commercial primate chow, fresh fruit and tap water ad libitum. On the day cf the studies, tive animais were in jected with factor Xa 0.45 UIkg together with phosphatidylcholinefphosphati dylserine (PC/PS) 56 nmollkg (Group A, low dose). A second group cf 6 ani mais was injected twice with FXa 1.2 Ulkg and PC/PS 200 nmol/kg at times O and 5h (group B, high dose). Three animais in each group were injected with interleukin-6 (IL-6) 8h before the administration of FXa, as a part of a wider study designed to assess IDe effect cf IL-6 on the coagulation and fibrinolytic respcnses in DIC. IL-6 pretreatment had no effect on yWf and propeptide lev els, rad the results from the two subgroups are iherefore pooied in the present report. Blood was collected from a posterior saphenous vein before and 2,5, 10, 20, 30 min and 1h after each injection of FXa, and subsequently at least every 2h up te 12h. Later samples were drawn after 24 and 48 h. The high dose FXa protocol caused a venous collapse after the first injection, preventing blood sampling for the first 30 min. This problem did net occur after the second injec tion, ailowing normal sampling. Ail injections md biood sampling were donc under light generai anesihesia (ketamine 7 mgi1g).
Fibrinogen was measured by a thrombin-initiated clotiing rate assay (Clauss's assay), using reagents obtained from Diagnostica Stage (Asnières, France). Thrombin-antithrombin itt complexes and prothrombin fragment 1+2 were measured by ELISA (Enzygnost TAT and Enzygnost 1+2, Behring). Fibrinopeptide A was measured by using a competitive ELISA after removal of fibrinogen by Bentonite absorption (Asserachrom FPA, Diagnostica Stago).
Resuits
Characteristics o! die Propeptide FUSA The assay for the propeptide (vWf:Agll) is a capture ELISA, using 2 monoclonal antibodies as a catching layer, and a third monoclonal antibody coupled to alkaline phosphatase for detection. We observed a linear relationship between plasma dilutions md optical density (0D405) over a range cf normal pooled plasma (NPP) dilutions from 1:10 te 1:640 (Fig. lA) . We also used purified propeptide as a standard, and found a propeptide concentration of 720 ± 43 nglml (n = 5) in normal pooled plasma-This value is at least ten fold lower than most estimates cf plasma vWf (10~sgIml) (16, 20) . 1f die molar ratio cf vWf (260 W) and the propeptide (97 W) is taken into account, the concentration cf propeptide is stili approximately 5 times lower than vWf. The propep tide signal detected in NPP at a dilution of 1:320-l :640 corresponds to a sensitivity of <2.5 nglml (<25 pM, assuming a molecular weight cf 97 kD). The correlation coefficient between repeat measurements was 0.93.
We determined the propeptide plasma levels in 30 normal individuais (Fig. lB) . The values ranged from 69 te 167% (102 ± 23%, mean ± SD). These results indicate a smaller variation among normal individuais for die propeptide than for vWf (range 47-185%, mean ± SD, 109 ± 33). We aise studied 14 patients with type III von Willebrand's disease (plasma vWf less than 1%). Propeptide levels were below the limit cf detection (less than 3%) in ail patients, confirming the specific ity cf our assay (Fig. I B) .
We observed a weaker signai with baboon plasma than with human plasma (Fig. lA) . Although ail three antibodies tested individually react with baboon propeptide, die likeliest explanation is that die anti- Plasma Propeptide Increases afler DDA VP Administration DDAVP is known to increase plasma vWf levels. In vitro, propep tide is released along with vWf from the endothelial cells. The plasma propeptide should therefore also increase after the administration of DDAVP. vWf and propeptide were measured in 9 normal individuals before and I h after the iv. injection of DDAVP (Fig. 2) . As expected, the plasma vWf level rose from 110 ± 12% to 272 ± 10% (mean ± SEM, p <0.0001) ( Fig. 2A ). There was a much more marked rise in propep tide, from 106 ± 8(0879 ± 67% (p <0.0001) (Fig. 2B) . When expressed as actual concentrations (using the propeptide concentration of normal pooled plasma (0.72~ig/ml) as a conversion factor), propeptide rose from 0.77 ± 0.06 te 6.33 ± 0.48 p.g/ml I h after the DDAVP injection, representing a mean increase cf 5.56 ± 0.47 p.gIml. This value com B pares with a mean increase in vWf of 16.20 ± 1.09 jiglml (assuming a concentration of 10 .ag/ml in the pooled plasma used as a standard (16, 23) . Expressed in molar units, the mean increases were 57 nM for pro peptide and 62 nM for vWf, assuming molecular weights of 97 and 260 kD respectively. These two values are quite similar, and compat ible with the in vitro observation that vWf and propeptide are stored and released in a 1:1 ratio. Thus although the amounts released from the endothelium are quite similar, the increase in propeptide level is much more impressive than the increase in vWf when expressed as a percentage of normal plasma.
To estimate the tum-over of the propeptide, 5 normal individuals
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were injected with DDAVP, and propeptide and vWf were itieasured VWD after I, 3 and 6 h (Fig. 3) . Following a mean initial 4.8 fold increase after I h, the propeptide values decreased by >70% over the next 5 h. Although these experiments do net allow a formaI determination, we can estimate the circulating haif-life to be in the order of 3 h. The decrease in vWf level was much less pronounced, <18% between I h and 6 h, in accordance with the much longer half-life reported for vWf of approximately 12h (23).
Plasma vWf and Propeptide Levels in Experimental DIC
We next investigated the changes in vWf and its propeptide follow ing activation of coagulation. We chose a DIC model in the baboon, which allows the time-controlled generation cf intravascular thrombin by injection of FXa. Five baboons were injected with a single dose of FXa (0.45 UIKg), together with phospholipids. This resulted in a very rapid and transient increase in the plasma levels of markers ofthrombin generation. Prothrombin fragment 1+2 increased sharply to a maximum at 2 min after the injection of FXa, and then decreased very rapidly, to retum to basal levels after 3-4 h. A very similar profile was observed with the thrombin-antithrombin complex (Fig. 4A) . We also observed a rapid increase in fibrinopeptide A (FPA), together with a significant de crease in fibrinogen levels (from 1.95 ± 0.17 to 0.98 ± 0.17 gll after 10 mi p = 0.001) (Fig. 4B ). Fibrinogen levels recovered over the sub sequent 12 h and were increased over prestimulation values by 24 h. These data confirm that an injection cf FXa induces intravascular gen eration of thrombin, which in tom induces the formation of fibrin. The period of fibrin generation is very brief, as is indicated by the fibrine- peplide A levels, which return b baseline 30-60 min after the initial peak. lnterestingiy, die piatelet levels were very utIle affected (Fig. 4C ). We observed a small decrease from 318,00010 252,000/mm3 at 2 mm, but (lie levels returned 10 305,000fmm3 after 5 min and re mained stable al ail later lime points. The WBC counts also decreased abruptly by 33% at 2 mm, but retumed (o pre-stimulation leveis by 30 min and increased over the prestimulation values for the next 12 h (Fig. 4C) . The levels of vWf increased ver)' rapidly, but the increases were re markabiy smali. The values increased by only 1.5 fold (Fig. 5) . Such in creases wouid easily escape detection were it not for the detaiied time course feasibie in Ibis model: the increase in vWf was detected al 2-5 min in ail animais studied. In marked contrast, the propeptide lev els rose much more strikingly, with a maximum increase of 3.5 foid al 30 min. The values returned 10 near normai by 6h, confirming LItaI the propeptide has a rapid turnover. Since the FXa-induced activation of coagulation is very brief, as indicated by LIte rapid normaiization of FPA, il is unlikely that the decrease in plasma propeptide is slowed down by ongoing release.
A second group of 6 animaIs was injected twice with a high dose of FXa (1.2 UIkg, together with phospholipids) al lime O and 5h. The re sults for FPA, thrombin fragments 1+2, and the thrombin-antithrombin compiex were qualitatively very similar, with a second peak of each marker after the second stimulation. After each injection there was an almosl compiete depletion of fibrinogen (not shown). The first injection caused a rapid 5.5 foid increase in plasma propeptide at 30 mm, fol iowed by a rapid decline 10 near normal values within 5 h (Fig. 6A) . vWf leveis underwent a rapid 1. tion. vWf increased again to 234% over LIte baseline level, and de creased oniy ver)' siowly over the subsequent 24h. Again, these obser vations suggesl lItaI propeplide has a shorl half-life of approx. l-2h. In contrast, vWf remained eievated up 10 al least 24 h after Ihe beginning of lIte study, in accordance with ils longer half-iife. The high doses of FXa had a more pronounced effecl on platelel counts (Fig. 6B) . A decrease from 330,000/mm3 to 169,000!mm3 al 30 min was observed, foliowed by a partial resloration 10 252,000/mm3 al 5h. The second injection of FXa caused a rapid drop (o I 28,000/mm3 afler 2 min (i.e. a 50% decrease), and a partial restoration 10 199,000Imm3 and 245 ,000/mm3 10 min and 2h later respectively. The transient drop in WBC count observed in bIte low dose group was nol found afler Ihe firsl injeclion of the higIt dose of FXa, presumably be cause blood could not be drawn during lIte first 30 mm, due to a tran sient venous collapse after FXa (Fig. 6B) . Afler one hour, the WBC count had increased b 15,300 ± 1600/mm3 ami remained stable over 
Discussion
This study describes an ELISA for the quantification of the propep tide. The assay is simple and reproducible, ami can be applied ta large numbers of samples. Since monoclonal antibodies are used, their avail abiiity is unlimited. Our assay is specific for the propeptide, as shown by the absence of a signal in patients with complete vWf deficiency (von Willebrand's disease type III). Both propeptide and vWf result from the cleavage of a common precursor, pro-vWf (1). Accordingly, the antibodies to propeptide also recognize pro-vWf. Although cultured endothelial cells release some uncleaved pro-vWf (32), this precursor is not found in normal plasma (26) , suggesting that in vivo cleavage is completed either before or very rapidly after secretion. It is therefore most unlikely that pro-vWf contributes to the immunoreactivity detect ed in our propeptide assay.
in vitro experiments have shown thatvWf is stored in Weibel-Palade bodies along with equimolar amounts of its propeptide (25, 33) . Stimu lation of exocytosis is therefore expected to cause the release of equi molar amounts of the twa moieties. Our in vivo findings support this observation. One hour after the injection of DDAVP Lo normal individ uals, the increases in plasma levels of propeptide and vWf (expressed in molar units) are quite similar. We determineil the propeptide plasma level to be approx. 0.7 p.gIml, which is at least 10 times lower than most estimates for plasma vWf (16, 23) . Even after conversion to molar units, the propeptide level is approximately 5 times lower than vWf. This Iower basal level is due to the rapid turnover of the propeptide. Our observations in bath humans and baboons suggest that the circulating half-life is Iess than 3 h. ibis is probably an overestimate, given the continuing effect of DDAVP (which bas itself a half-life of approx. lb) on endothelial secretion. Thus when equimolar amounts of vWf and propeptide are secreted, the increase in plasma propeptide -expressed in relative units -is much more apparent due ta its low pre-stimulation value. Given these ldnetic properties, the propeptide is well suited for the assessment of acute endothelial secretion. Exocytosis occurs in a polarized fashion ta the baso-lateral side of the cells (17) . A part of the vWf released may remain trapped in the subendothelium and fail ta reach the plasma. Although the propeptide binds ta bovine type I collagen in vitro, there is no evidence for propep tide adhesion ta the subendothelium in celI culture experimenLs (25) . Thus, the molar amounts of vWf entering the bloodstream should be smaller than those of propeptide. The increases in plasma vWf and pro pepLide after DDAVP (in molar units) are ver)' similar. Although we certainly cannot rule out the possibility that some vWf is retained in a biologically active form in the subendothelium, these observations sug gest that retained vWf represents only a small proportion of the vWf released from Lhe endothelial cells.
Since vWf is stored not only in the endothelium, but aiso in mega karyocytes and piatelets (7) , the interpretation of plasma propeptide levels needs ta take the possible contribution from platelets into ac count. In vivo release of propeptide from platelets is very unlikely in the case of DDAVP, which bas minimal effects on platelet activaLion. In a previous study, we found only minimal increases in the surface ex pression of granule membrane proteins (31) . The propeptide level in serum, which would be expected to contain ail releasable platelet pro peptide, is 2.8 fold higher than in plasma, whereas this ratio. is 1.3 in the case of vWf (not shown). In the INC studies, plateleL activation occur ring in the process of microthrombi formation could induce propeptide release. In the iow-dose group, where the propeptide level increased more than 3 fold, we only observed a small decrease of piatelet counts the foilowing 4h. A sharp decrease ta 10,100 ± 2300/mm3 2 min after Lhe second injecLion was again observed, followed by a retum ta pre injection values 30 min later. 10-5. o -C û) Q e o n 3 00 after 2 mm, followed by normalization already after 5 min. In the high dose FXa group in which more obvious platelet activation (as reflected by a 50% lowering of platelet counts) occured, platelet-derived propep tide could account in part for the increase in plasma propeptide. AI though platelet-derived propeptide is unlikely to account entirely for the >5 fold increase in plasma propeptide, these considerations under score our conclusion that DIC is a weak stimulus for endothelial vWf release (see below).
Exocytosis from Weibel-Palade bodies also results in transiocation of P-selectin from the granule membrane to the ceil surface, facilitating leukocyte rolling, which mediates adhesion to the endothelium and sub sequent extravasation (34, 35) . In vitro, following histamine-induced exocytosis, the surface expression of P-selectin is very transient: after a peak aL 2 mm, it is internalized by endocytosis within 30 min (35) . lnterestingly, the injection of FXa causes a rapid and transient decrease in WBC count, with a time course which is strikingly similar to these in vitro observations. The decrease also correlates closely with the in crease in propeptide. The observed decrease is compatible with leuko cyte adhesion to P-selectin newly exposed after exocytosis of the Weibel-Palade bodies. This interpretation provides further support for the notion that propeptide is a marker of endothelial exocytosis.
DDAVP is used in the clinical setting to increase plasma vWf levels and reduce bleeding time in patients with von Willebrand disease and other bleeding disorders (il). Although it bas no effect on vWf release from cultured endothelial cells, DDAVP is assumed to induce vWf re lease from Weibel-Palade bodies in vivo. DDAVP bas no direct secre tory effect on platelets, the only alternative source of cellular vWf (31) . Our results confirm the observations of McCarroll et al. showing Ébat DDAVP induces a rapid increase in plasma propeptide as well as vWf (36) , and strengthen the view that DDAVP induces exocytosis from WP bodies. The effect of DDAVP on vWf levels could conceivably be due to recirculation of extracellular vWf sequestered from the blood stream (e.g. in the spleen). However, the parallel increase of propeptide and vWf in equivalent amounts argues against this hypothesis, given the distinct structures and adhesive properties of these two proteins.
The DIC model in baboons used in the present report makes it pas sible to examine the activation of coagulation and fibrinolytic respons es with a detailed time course. This model is therefore well suited to study the effect of DIC on vascular function, in particular on endothe liai secretion. fle low dose FXa injection caused a modest, 50% in crease in plasma vWf. This would have escaped detection were it not for early collection of samples, showing that the increase occured with in 2-5 min. Indeed, most post-stimulation values overlap with the range of normal values as defined for clinical use (16) . In contrast, propeptide increased more than 3 fold, with an equally rapid time course. A higher dose of FXa induced a larger, 5.5 fold increase in propeptide levels, in dicating a dose-related response to FXa. A second injection of FXa 5 h later was stiil capable of inducing a second peak of propeptide, which was only 30% lower than the first peak. The rapid, simultaneous in crease in vWf and propeptide strongly suggest Ébat FXa-induced DIC induces secretion from pre-formed endothelial stores. tiowever, our re suits indicate Ébat vWf release in this DIC model is surprisingly modest. Although the FXa injected generated enough thrombin to decrease librinogen levels by 50% (group A) or 100% (group B), vWf leveis went up by only 50% or 90% respectively. Increases in propeptide were more obvious, and in the low dose group were helpfùl in determining that vWf release occured at ail. Hence, thrombin and fibrin are quite inefficient at raising plasma vWf. These observations stand in contrast with their strong effect on vWf release in cultured celis, when com pared to other secretagogues such as epinephrine (9, 10, Vischer and Wollheim, submitted). This discrepancy could be explained in part by rapid inactivation of thrombin at the endothelial surface, e.g. by ceil associated antithrombin III.
In conclusion our new assay for plasma propeptide could provide a valuable marker of acute secretion from endotheliai ceils in vivo, essen tialiy due to the rapid turnover of the protein. Although some plasma propeptide could derive from platelets, this is unlikeiy to be of major significance except in situations of massive platelet activation such as vasculitis or acute respiratory distress syndrome. Propeptide levels may be useful to determine weak secretory responses, as in our DIC model or in other situations such as physical activity, and differentiate them from non-specific increases due to hemoconcentration and/oçdehydra tion. Future work should also determine whether propeptide, given its simpler structure and kinetic properties, could be a more reliable mark er of endothelial secretion than vWf in chronic vascular disorders.
